Skip to content

Regeneron Acquires Oxular to Advance Retinal Disorder Treatments

๐‘๐ž๐ ๐ž๐ง๐ž๐ซ๐จ๐ง ๐€๐œ๐ช๐ฎ๐ข๐ซ๐ž๐ฌ ๐Ž๐ฑ๐ฎ๐ฅ๐š๐ซ ๐ญ๐จ ๐€๐๐ฏ๐š๐ง๐œ๐ž ๐‘๐ž๐ญ๐ข๐ง๐š๐ฅ ๐ƒ๐ข๐ฌ๐จ๐ซ๐๐ž๐ซ ๐“๐ซ๐ž๐š๐ญ๐ฆ๐ž๐ง๐ญ๐ฌ

๐Ÿ‘ Regeneron Pharmaceuticals has acquired Oxular, a UK-based company specializing in ocular delivery technology for retinal disorders. Oxular's lead candidate, OXU-001, uses their proprietary Oxulumis microcatheter for targeted delivery of dexamethasone to the eye, potentially offering up to one year of effectiveness.

๐Ÿ‘จโ€โš•๏ธ This acquisition allows Regeneron to enhance treatment options for retinal disorders like diabetic macular edema (DME), improving patient care in ophthalmology.